Stock Fundamentals

Company Information

Company Name
Denali Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US24823R1059
CIK: 0001714899
CUSIP: 24823R105
Currency: USD
Full Time Employees: 507
Phone: 650 866 8547
Fiscal Year End: December
IPO Date: Dec 08, 2017
Description:

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Address:

161 Oyster Point Boulevard, South San Francisco, CA, United States, 94080

Directors & Officers

Name Title Year Born
Dr. Ryan J. Watts Ph.D. Co-Founder, President, CEO & Director 1976
Dr. Alexander O. Schuth M.D., Ph.D. Co-Founder, CFO, COO & Secretary 1973
Dr. Dana Andersen Chief Technical and Manufacturing Officer NA
Mr. Joe Lewcock Ph.D. Chief Scientific Officer NA
Mr. Chris Walsh J.D. General Counsel NA
Ms. Cindy Dunkle Chief People Officer NA
Ms. Katie Peng M.B.A. Chief Commercial Officer 1971
Mr. Peter Chin M.D. Acting Chief Medical Officer & Head of Development 1968

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 06, 2026 Alexander O Schuth N/A Sale 17.22K $16.50 $284.10K
Jan 06, 2026 Ryan J Watts N/A Sale 35.20K $16.50 $580.77K
Aug 13, 2025 Carole Ho N/A Sale 806.00 $14.64 $11.80K
Aug 12, 2025 Alexander O Schuth N/A Sale 2.94K $13.58 $39.88K
Aug 12, 2025 Carole Ho N/A Sale 2.94K $13.58 $39.88K
Jul 09, 2025 Ryan J Watts N/A Sale 495.28K $15.00 $7.43M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Vanguard Group Inc 13.06M Dec 31, 2025 8.23% $0.00 8.88%
BlackRock Inc 13.03M Mar 31, 2026 8.21% $0.00 2.51%
Baillie Gifford & Co Limited. 12.07M Mar 31, 2026 7.60% $0.24 -1.99%
T. Rowe Price Investment Management,Inc. 8.52M Mar 31, 2026 5.37% $0.11 0.22%
Temasek Holdings Ltd. 7.01M Mar 31, 2026 4.42% $0.44 0.00%
State Street Corp 6.27M Mar 31, 2026 3.95% $0.00 0.14%
NORGES BANK 5.12M Dec 31, 2025 3.23% $0.01 29.70%
FMR Inc 4.58M Mar 31, 2026 2.88% $0.00 -24.96%
UBS Asset Mgmt Americas Inc 4.43M Mar 31, 2026 2.79% $0.02 -11.06%
The Goldman Sachs Group Inc 4.41M Mar 31, 2026 2.78% $0.01 14.90%
Baker Bros Advisors LP 3.73M Mar 31, 2026 2.35% $0.41 0.00%
Geode Capital Management, LLC 3.73M Mar 31, 2026 2.35% $0.00 7.78%
Holocene Advisors, LP 3.20M Mar 31, 2026 2.01% $0.15 1.35%
AllianceBernstein L.P. 2.89M Mar 31, 2026 1.82% $0.02 -18.67%
Dimensional Fund Advisors, Inc. 2.69M Mar 31, 2026 1.70% $0.01 13.39%
UBS Group AG 2.57M Mar 31, 2026 1.62% $0.01 6.93%
Pictet Asset Manangement SA 2.56M Mar 31, 2026 1.61% $0.05 92.53%
Capital Research Global Investors 2.51M Mar 31, 2026 1.58% $0.01 -32.57%
T. Rowe Price Associates, Inc. 2.46M Mar 31, 2026 1.55% $0.01 -37.07%
Fisher Asset Management, LLC 2.44M Mar 31, 2026 1.54% $0.02 -5.89%

Shares Statistics

Shares Outstanding: 158.71M
Shares Float: 144.27M
% Insiders: 913.10%
% Institutions: 9,958.20%
Short % Float: 9.33%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Scottish Mortgage Ord 7.04M 4.44% ▲ 0.00% Mar 31, 2026
2 Vanguard Total Stock Mkt Idx Inv 4.26M 2.68% ▲ 0.39% Apr 30, 2026
3 iShares Russell 2000 ETF 3.34M 2.10% ▲ 0.85% Apr 30, 2026
4 State Street® SPDR® S&P® Biotech ETF 3.16M 1.99% ▼ 0.71% Apr 30, 2026
5 Vanguard Small Cap Index 3.11M 1.96% ▼ 0.14% Apr 30, 2026
6 Vanguard US Growth Investor 3.04M 1.91% ▲ 0.00% Mar 31, 2026
7 Baillie Gifford US Equity Growth 3.04M 1.91% ▲ 0.00% Mar 31, 2026
8 T. Rowe Price Small-Cap Stock 2.33M 1.47% ▲ 7.11% Mar 31, 2026
9 T. Rowe Price US Small-Cap Core Equity 2.33M 1.47% ▲ 6.95% Mar 31, 2026
10 American Funds SMALLCAP World A 2.21M 1.39% ▼ 4.34% Mar 31, 2026

Valuation Metrics

Enterprise Value: $2.29B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $3.07B
EBITDA: $-531.76M
Book Value: $5.84
Earnings/Share: $-2.88
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -26.95%
ROE (TTM): -49.59%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -100.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 9.16x 0.01x 0.11x N/A -0.02x
2024-12-31 8.46x 0.01x 0.11x N/A -0.02x
2023-12-31 13.65x 0.01x 0.11x N/A -0.04x
2022-12-31 3.77x 0.01x 0.29x -23.06x -0.02x
2021-12-31 2.37x 0.01x 0.31x -22.43x -0.02x
2020-12-31 20.86x 0.00x 0.28x 3.53x 0.07x
2019-12-31 9.48x 0.01x 0.29x -14.01x -0.02x
2018-12-31 14.67x 0.03x 0.17x -23.72x -0.49x
2017-12-31 28.92x 0.00x 0.04x -46.11x 0.00x
2016-12-31 19.98x 0.00x 0.06x N/A 0.00x
2015-12-31 9.60x 0.00x 1.43x -153.02x 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about DNLI.US!